AIHTA - Publications - Search - Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC)

Rothschedl, E. and Grössmann, N. (2023): Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC). Fact Sheet Nr. 153.

[thumbnail of Fact Sheet Nr.153.pdf]
Preview
 PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
139kB

Item Type:Horizon Scanning of Medicines
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WI Digestive system > WI 700-770 Liver. Billary tract
Language:English
Series Name:Fact Sheet Nr. 153
Deposited on:17 Nov 2023 14:59
Last Modified:14 Dec 2023 12:02

Repository Staff Only: item control page